首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Delivery of foreign antigens by engineered outer membrane vesicle vaccines
【24h】

Delivery of foreign antigens by engineered outer membrane vesicle vaccines

机译:通过工程化的外膜囊泡疫苗递送外来抗原

获取原文
获取原文并翻译 | 示例
       

摘要

As new disease threats arise and existing pathogens grow resistant to conventional interventions, attention increasingly focuses on the development of vaccines to induce protective immune responses. Given their admirable safety records, protein subunit vaccines are attractive for widespread immunization, but their disadvantages include poor immunogenicity and expensive manufacture. We show here that engineered Escherichia coli outer membrane vesicles (OMVs) are an easily purified vaccine-delivery system capable of greatly enhancing the immunogenicity of a low-immunogenicity protein antigen without added adjuvants. Using green-fluorescent protein (GFP) as the model subunit antigen, genetic fusion of GFP with the bacterial hemolysin ClyA resulted in a chimeric protein that elicited strong anti-GFP antibody titers in immunized mice, whereas immunization with GFP alone did not elicit such titers. Harnessing the specific secretion of ClyA to OMVs, the ClyA-GFP fusion was found localized in OMVs, resulting in engineered recombinant OMVs. The anti-GFP humoral response in mice immunized with the engineered OMV formulations was indistinguishable from the response to the purified ClyA-GFP fusion protein alone and equal to purified proteins absorbed to aluminum hydroxide, a standard adjuvant. In a major improvement over current practice, engineered OMVs containing ClyA-GFP were easily isolated by ultracentrifuga-tion, effectively eliminating the need for laborious antigen purification from cell-culture expression systems. With the diverse collection of heterologous proteins that can be functionally localized with OMVs when fused with ClyA, this work signals the possibility of OMVs as a robust and tunable technology platform for a new generation of prophylactic and therapeutic vaccines.
机译:随着新的疾病威胁的出现和现有病原体对常规干预的抵抗力越来越强,人们的注意力越来越集中在疫苗的开发上,以诱导保护性免疫反应。鉴于其令人钦佩的安全记录,蛋白质亚单位疫苗对于广泛的免疫颇具吸引力,但其缺点包括免疫原性差和制造昂贵。我们在这里显示工程化的大肠杆菌外膜囊泡(OMVs)是一种易于纯化的疫苗输送系统,能够在不添加佐剂的情况下大大增强低免疫原性蛋白抗原的免疫原性。使用绿色荧光蛋白(GFP)作为模型亚基抗原,GFP与细菌溶血素ClyA的遗传融合产生了一种嵌合蛋白,该蛋白在免疫小鼠中引起了很强的抗GFP抗体效价,而仅用GFP免疫并没有引起这种效价。 。利用ClyA对OMV的特异性分泌,发现ClyA-GFP融合物位于OMV中,从而产生了工程重组OMV。用工程化的OMV制剂免疫的小鼠中的抗GFP体液反应与仅对纯化的ClyA-GFP融合蛋白的反应没有区别,并且等同于被标准佐剂氢氧化铝吸收的纯化蛋白。在当前实践的一项重大改进中,通过超速离心可以轻松分离出含有ClyA-GFP的工程OMV,从而有效地消除了从细胞培养表达系统中纯化费力的抗原的需求。与ClyA融合时,可以通过OMV功能定位的异源蛋白种类繁多,这项工作表明了OMV作为新一代预防和治疗疫苗的强大且可调节的技术平台的可能性。

著录项

  • 来源
  • 作者单位

    School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853;

    rnDepartment of Microbiology and Immunology, Cornell University,Ithaca, NY 14853 Institut fuer Virologie, Freie UEniversitat Berlin, 10015 Berlin, Germany;

    rnDepartment of Microbiology and Immunology, Cornell University,Ithaca, NY 14853;

    rnDepartment of Biomedical Sciences, Cornell University, Ithaca, NY 14853;

    rnDepartment of Biomedical Engineering, Cornell University, Ithaca, NY 14853;

    rnSchool of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853;

    rnSchool of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853 Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    protein subunit; adjuvant;

    机译:蛋白质亚基佐剂;
  • 入库时间 2022-08-18 00:41:16

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号